• Critical review outlines biomarker-guided treatment selection in metastatic CRC

    A structured narrative review separately examines mismatch repair-deficient/MSI-H and microsatellite-stable disease, distinguishing established treatments from investigational strategies based on molecular alterations including BRAF V600E and HER2. (Crit Rev Oncol Hematol)